{"id":"W3198912637","doi":"10.1158/1078-0432.ccr-21-1466","title":"FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"U.S. Food and Drug Administration; National Institutes of Health","keywords":"Nivolumab; Ipilimumab; Regimen; Pemetrexed; Carboplatin; Gemcitabine; Chemotherapy regimen; Clinical trial","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005302303,0.00008469468,0.0002612405,0.00005921868,0.00008928431,0.00001250327,0.0000849791,0.00005441654,0.0002791905],"category_scores_gemma":[0.0001665008,0.00004840003,0.0001153098,0.0003180115,0.0003258179,0.00004082827,0.0000361729,0.0001313353,0.000005905666],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002765182,"about_ca_system_score_gemma":0.0005097092,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000645914,"about_ca_topic_score_gemma":0.000733043,"domain_scores_codex":[0.9984528,0.0001674346,0.0003091704,0.0002860691,0.0005224987,0.0002620716],"domain_scores_gemma":[0.9982033,0.001210372,0.00004445027,0.0002669749,0.0001738063,0.0001010498],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02103605,0.00749283,0.9025328,0.0003037992,0.0003224838,0.00009897166,0.0001899804,0.0001451449,0.001972013,0.0006962252,0.002832003,0.06237772],"study_design_scores_gemma":[0.01456247,0.007519382,0.9516584,0.0002508762,0.0001182824,0.000007169926,0.0005787925,0.00215889,0.005987934,0.0006555826,0.01639381,0.0001084538],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916177,0.003463893,0.0000266718,0.003271951,0.00007715823,0.0009450001,0.00009688684,0.000007144419,0.0004936226],"genre_scores_gemma":[0.9924409,0.002547887,0.0001608554,0.00007604912,0.0001215265,0.0004809532,0.00009165503,0.00001687732,0.004063274],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06226927,"threshold_uncertainty_score":0.305694,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1791777639283689,"score_gpt":0.4791178402547532,"score_spread":0.2999400763263843,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}